Entera Bio Statistics
Total Valuation
Entera Bio has a market cap or net worth of $541.57 million. The enterprise value is $276.08 million.
| Market Cap | 541.57M |
| Enterprise Value | 276.08M |
Important Dates
The last earnings date was Friday, November 6, 2026, after market close.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Entera Bio has 174.14 million shares outstanding. The number of shares has increased by 64.72% in one year.
| Current Share Class | 174.14M |
| Shares Outstanding | 174.14M |
| Shares Change (YoY) | +64.72% |
| Shares Change (QoQ) | +187.56% |
| Owned by Insiders (%) | 0.87% |
| Owned by Institutions (%) | 18.57% |
| Float | 118.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.97 |
| P/TBV Ratio | 1.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 128.41, with a Debt / Equity ratio of 0.00.
| Current Ratio | 128.41 |
| Quick Ratio | 123.53 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.67 |
Financial Efficiency
Return on equity (ROE) is -20.33% and return on invested capital (ROIC) is -7.93%.
| Return on Equity (ROE) | -20.33% |
| Return on Assets (ROA) | -7.82% |
| Return on Invested Capital (ROIC) | -7.93% |
| Return on Capital Employed (ROCE) | -6.70% |
| Weighted Average Cost of Capital (WACC) | 13.86% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.09M |
| Employee Count | 27 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.87% in the last 52 weeks. The beta is 1.46, so Entera Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.46 |
| 52-Week Price Change | +6.87% |
| 50-Day Moving Average | 2.90 |
| 200-Day Moving Average | 1.99 |
| Relative Strength Index (RSI) | 54.06 |
| Average Volume (20 Days) | 330,168 |
Short Selling Information
The latest short interest is 7.07 million, so 4.06% of the outstanding shares have been sold short.
| Short Interest | 7.07M |
| Short Previous Month | 5.55M |
| Short % of Shares Out | 4.06% |
| Short % of Float | 5.97% |
| Short Ratio (days to cover) | 9.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -18.41M |
| Pretax Income | -29.43M |
| Net Income | -29.43M |
| EBITDA | -18.38M |
| EBIT | -18.41M |
| Earnings Per Share (EPS) | -$0.40 |
Balance Sheet
The company has $265.88 million in cash and $397,000 in debt, with a net cash position of $265.49 million or $1.52 per share.
| Cash & Cash Equivalents | 265.88M |
| Total Debt | 397,000 |
| Net Cash | 265.49M |
| Net Cash Per Share | $1.52 |
| Equity (Book Value) | 274.28M |
| Book Value Per Share | 1.58 |
| Working Capital | 274.31M |
Cash Flow
In the last 12 months, operating cash flow was -$15.79 million and capital expenditures -$51,000, giving a free cash flow of -$15.84 million.
| Operating Cash Flow | -15.79M |
| Capital Expenditures | -51,000 |
| Depreciation & Amortization | 32,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -15.84M |
| FCF Per Share | -$0.09 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Entera Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -64.72% |
| Shareholder Yield | n/a |
| Earnings Yield | -13.01% |
| FCF Yield | -2.92% |
Analyst Forecast
The average price target for Entera Bio is $9.75, which is 213.51% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.75 |
| Price Target Difference | 213.51% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Entera Bio has an Altman Z-Score of 32.22 and a Piotroski F-Score of 2.
| Altman Z-Score | 32.22 |
| Piotroski F-Score | 2 |